CD34-Positive Blast Count and p53 Expression in Bone Marrow Biopsies of Patients with Low-Risk Myelodysplastic Syndromes: Potential Predictive Tools of Response to Erythropoietin Stimulating Agents
Conclusions: Our study reinforces the role of BM biopsy as diagnostic tool in MDSs, being also able to supply information related to response to ESAs and to its loss over time.Pathobiology
Source: Pathobiology - Category: Pathology Source Type: research
More News: Blood Transusion | Bone Marrow Aspiration and Biopsy | Clinical Trials | Iron | Myelodysplastic Syndrome | Pathology | Study